Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet-Reference-Cited by-同舟云学术

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

Published:2021-09 Issue:9 Volume:8 Page:e658-e665
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Alvarez-Larrán Alberto,Sant'Antonio Emanuela,Harrison Claire,Kiladjian Jean-Jacques,Griesshammer Martin,Mesa Ruben,Ianotto Jean Christophe,Palandri Francesca,Hernández-Boluda Juan Carlos,Birgegård Gunnar,Nangalia Jyoti,Koschmieder Steffen,Rumi Elisa,Barbui Tiziano

Publisher

Elsevier BV

Subject

Hematology

Reference54 articles.

1. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2;Nangalia;N Engl J Med,2013

2. Somatic mutations of calreticulin in myeloproliferative neoplasms;Klampfl;N Engl J Med,2013

3. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia;Rotunno;Blood,2014

4. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes;Rumi;Blood,2014

5. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations;Al Assaf;Haematologica,2015

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia;2024-08-18

2. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon;British Journal of Haematology;2024-04-08

3. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options;Annals of Hematology;2024-03-04

4. Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients;Blood Cancer Journal;2024-01-23

5. Ph-Negative Chronic Myeloproliferative Neoplasms;Comprehensive Hematology and Stem Cell Research;2024